The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Open accessAbstract
PURPOSE: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Eighteen randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: For human epidermal growth factor receptor 2 (HER2)–negative patients with gastric adenocarcinoma (AC) and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5, first-line therapy with nivolumab and chemotherapy (CT) is recommended. For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS ≥ 5, first-line therapy with nivolumab and CT is recommended. First-line therapy with pembrolizumab and CT is recommended for HER2-negative patients with esophageal or GEJ AC and PD-L1 CPS ≥ 10. For patients with esophageal squamous cell carcinoma and PD-L1 tumor proportion score ≥ 1%, nivolumab plus CT, or nivolumab plus ipilimumab is recommended; for patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10, pembrolizumab plus CT is recommended. For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic AC, trastuzumab plus pembrolizumab is recommended, in combination with CT. For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended. For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Self-citationPatient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Alpert, A. B., Gampa, V., Lytle, M. C., Manzano, C., Ruddick, R., Poteat, T., Quinn, G. P., & Kamen, C. S. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2021.03.007 · Cited by 73
Cited by
Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02005 · Cited by 1,069
Self-citationShitara, K., Lordick, F., Bang, Y.-J., Enzinger, P., Ilson, D., Shah, M. A., Van Cutsem, E., Xu, R.-H., Aprile, G., Xu, J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00620-7 · Cited by 822
Self-citationShah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02465-7 · Cited by 681
Self-citation
Metadata
- Authors
- Shah, M. A., Kennedy, E. B., Alarcon-Rozas, A. E., Alcindor, T., Bartley, A. N., Malowany, A. B., Bhadkamkar, N. A., Deighton, D. C., Janjigian, Y., Karippot, A., Khan, U., King, D. A., Klute, K., Lacy, J., Lee, J. J., Mehta, R., Mukherjee, S., Nagarajan, A., Park, H., Saeed, A., Semrad, T. J., Shitara, K., Smyth, E., Uboha, N. V., Vincelli, M., Wainberg, Z., & Rajdev, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2023-03-01
- Volume
- 41
- Issue
- 7
- Pages
- 1470-1491
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4313553529
- Cited by
- 215
- References
- 6
- FWCI
- 22.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. https://app.cochat.ai/papers/10.1200/jco.22.02331
- The paper
- Shah, M. A., Kennedy, E. B., Alarcon-Rozas, A. E., Alcindor, T., Bartley, A. N., Malowany, A. B., Bhadkamkar, N. A., Deighton, D. C., Janjigian, Y., Karippot, A., Khan, U., King, D. A., Klute, K., Lacy, J., Lee, J. J., Mehta, R., Mukherjee, S., Nagarajan, A., Park, H., . . . Rajdev, L. (2023). Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.